Summary
Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, Inc. (NASDAQ:MAZE), completed a sale of 7,500 common shares on March 30, 2026, generating proceeds of $220,018. The shares traded between $29.2556 and $30.0173. On the same date he exercised options to acquire 7,500 Maze shares at an exercise price of $10.42, for a cash value of $78,150. After these moves, Dandekar’s direct ownership stands at 10,503 shares.
The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan that was adopted on September 29, 2025. The share disposition occurred against a backdrop of strong recent performance in the Maze stock, which has risen more than 200% over the last year, though InvestingPro analysis indicates the stock may be trading above its calculated Fair Value. Separately, MAZE has slipped about 6% in the most recent week.
Clinical and analyst developments
Maze has reported meaningful Phase 2 HORIZON data for MZE829, its APOL1 inhibitor under investigation for APOL1-mediated chronic kidney disease. The trial data showed a mean 35.6% reduction in urine albumin-to-creatinine ratio across a diverse participant population that included both diabetic and non-diabetic patients. These results were characterized in the company release as positive proof-of-concept findings.
Following the disclosure of the HORIZON data, several broker-dealers and research firms reiterated favorable ratings and published price targets. BTIG maintained a Buy rating with a $46.00 target. TD Cowen reiterated a Buy rating. Raymond James maintained a Strong Buy rating and set a $56.00 target. Truist Securities reiterated a Buy rating and assigned a $68.00 price target. Leerink Partners reiterated an Outperform rating and set a $50.00 target. The analyst responses underline broadly positive reception of the Phase 2 results among these firms.
Context and limitations
The insider sale was conducted through a prearranged plan, and the executive simultaneously exercised options, increasing his holdings through the option exercise while reducing holdings through the open-market sale. The information available does not specify any further trading intentions or additional insider activity beyond what is stated above. InvestingPro’s valuation comment reflects an analytical view that the stock may be above Fair Value, while the recent short-term price movement has been down approximately 6% over the past week.
For investors and market observers, the combination of insider option exercise, open-market sale under a 10b5-1 plan, and strong clinical readouts followed by multiple analyst reiterations presents a mixed set of data points to weigh alongside valuation signals.